List of Combigan drug patents

Combigan is owned by Allergan.

Combigan contains Brimonidine Tartrate; Timolol Maleate.

Combigan has a total of 11 drug patents out of which 11 drug patents have expired.

Expired drug patents of Combigan are:

  • US7320976
  • US8133890
  • US9770453
  • US9907801
  • US8354409
  • US8748425
  • US9907802
  • US9474751
  • US7030149
  • US7323463
  • US7642258

Combigan was authorised for market use on 30 October, 2007.

Combigan is available in solution/drops;ophthalmic dosage forms.

Combigan can be used as reduction of intraocular pressure in patients with elevated intraocular pressure or glaucoma, reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled iop, reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension, reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension, with comparable efficacy, and a reduction in specified adverse events, compared to brimonidine 0.2% tid, reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled iop. dose is one drop of combigan in the affected eye twice daily, reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension, with a reduction in specified adverse events, compared to brimonidine 0.2% tid, reduction of elevated intraocular pressure, reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension, with comparable efficacy to brimonidine 0.2% tid.

The generics of Combigan are possible to be released after 19 January, 2023.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7642258 ALLERGAN Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(9 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7320976 ALLERGAN Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(9 months ago)

US8133890 ALLERGAN Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(9 months ago)

US9770453 ALLERGAN Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(9 months ago)

US9907801 ALLERGAN Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(9 months ago)

US8354409 ALLERGAN Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(9 months ago)

US8748425 ALLERGAN Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(9 months ago)

US9907802 ALLERGAN Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(9 months ago)

US9474751 ALLERGAN Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(9 months ago)

US7030149 ALLERGAN Combination of brimonidine timolol for topical ophthalmic use
Apr, 2022

(9 months ago)

US7323463 ALLERGAN Combination of brimonidine and timolol for topical ophthalmic use
Jan, 2023

(12 days ago)

Drugs and Companies using BRIMONIDINE TARTRATE; TIMOLOL MALEATE ingredient

Market Authorisation Date: 30 October, 2007

Treatment: Reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled iop. dose is one drop of combigan in the affected eye twice daily; Reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension; Reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension, with comparable efficacy, and a reduction in specified adverse events, compared to brimonidine 0.2% tid; Reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension, with a reduction in specified adverse events, compared to brimonidine 0.2% tid; Reduction of intraocular pressure in patients with elevated intraocular pressure or glaucoma; Reduction of elevated intraocular pressure; Reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension, with comparable efficacy to brimonidine 0.2% tid; Reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled iop

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of COMBIGAN before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic